News & Updates

In individuals with psoriatic arthritis (PsA) who have inadequate response or intolerance to ≥1 csDMARD*, the monoclonal antibody risankizumab significantly improved manifestations of PsA, according to the 24-week findings of the phase III KEEPsAKE 1 trial.

Treatment with apremilast is effective in mild-to-moderate plaque psoriasis and has a consistent safety profile, results of a phase III study have shown.

Individuals with metabolic syndrome who are hospitalized for COVID-19 may have a greater risk for more severe COVID-19 disease, including an elevated risk of in-hospital mortality, acute respiratory distress syndrome (ARDS), and intensive care unit (ICU) admission, a recent prospective study showed.

The risk for hip fracture slightly increases following osteoporosis drug holidays after long-term therapy with risedronate compared with alendronate, a study has found, adding that future research must examine how best to lessen such risk.

The nonsteroidal topical aryl hydrocarbon receptor (AHR)-modulating agent tapinarof 1% trumped a vehicle control cream in reducing the severity and manifestations of plaque psoriasis, according to the phase III PSOARING 1 and 2 trials.

Adding aspirin to usual care did not lead to a reduced mortality rate in patients hospitalized with COVID-19, according to a study by the RECOVERY* Collaborative Group.

Epstein-Barr virus (EBV) may be the first trigger for the development of multiple sclerosis (MS) in most cases, says an expert.

Oral sitafloxacin was just as effective and safe as levofloxacin for the treatment of complicated and uncomplicated urinary tract infections (UTIs) in adults, according to a phase III study from China.

There is no apparent increased risk of deep vein thrombosis (DVT) following receipt of the COVID-19 vaccine, according to a study presented at ASH 2021.